Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake.
about
Antibody-based immunotherapy of solid cancers: progress and possibilitiesAntibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugarEndoS and EndoS2 hydrolyze Fc-glycans on therapeutic antibodies with different glycoform selectivity and can be used for rapid quantification of high-mannose glycansAntibody Drug Conjugates: Nonclinical Safety Considerations.N-glycan PK Profiling Using a High Sensitivity nanoLCMS Work-Flow with Heavy Stable Isotope Labeled Internal Standard and Application to a Preclinical Study of an IgG1 Biopharmaceutical.Near-IR Light-Mediated Cleavage of Antibody-Drug Conjugates Using Cyanine Photocages.Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates.Cystine-knot peptides: emerging tools for cancer imaging and therapy.Emerging formats for next-generation antibody drug conjugates.Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.Antibody-Based Treatment of Acute Myeloid Leukemia.LC-MS analysis combined with principal component analysis and soft independent modelling by class analogy for a better detection of changes in N-glycosylation profiles of therapeutic glycoproteins.The application of mathematical modelling to the design of bispecific monoclonal antibodies.Current progress in innovative engineered antibodies.Dose-related regulatory effect of intravenous immunoglobulin on dendritic cells-mediated immune response.Immunogenicity considerations for antibody-drug conjugates: a focus on neutralizing antibody assays.
P2860
Q26796542-8C643CEE-6EE1-46A5-8341-468C5A9550ADQ30275229-D804D923-B02E-402D-9713-DCAEC6A93383Q35526950-07BDA1F2-3A54-4EFA-A830-242325C80C01Q35686671-BBD779AF-1A01-4965-A8F7-9B0070C0CCADQ35967917-941D3081-596B-4A34-BF4A-ABC47CEF666AQ36133312-C65B7637-54CC-4747-B483-3AC9DE373762Q36551221-A8A932E5-6916-4741-933E-05BDD9736D52Q38212929-2263E090-AECB-4D1D-B17E-BE39E35BB575Q38243927-76FCB7A8-395E-434C-8765-7FAF63601CF6Q38386705-DF9537C1-0569-46D9-ACD4-50B740038D69Q38798481-C83DC515-9166-4818-A8D4-6CAE12CD3D55Q38979277-08CFE3FD-1342-43C3-80CD-759B3B055143Q39692794-C8925AF3-8C3C-48C2-AB13-BCFA5F6EDABFQ39972825-5DA2863F-5DAB-43E0-A208-60D782ED085DQ40077818-8B724251-743D-4405-A1E4-D5F12CF1381AQ42251007-FC63D9C3-BB8D-4B0B-8CFD-6B0F718CADADQ49831027-C63D5C86-DC43-4593-BFEC-EC7991B425AC
P2860
Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Proposed mechanism of off-targ ...... en by mannose receptor uptake.
@en
type
label
Proposed mechanism of off-targ ...... en by mannose receptor uptake.
@en
prefLabel
Proposed mechanism of off-targ ...... en by mannose receptor uptake.
@en
P2860
P1476
Proposed mechanism of off-targ ...... en by mannose receptor uptake.
@en
P2093
Boris Gorovits
Corinna Krinos-Fiorotti
P2860
P2888
P304
P356
10.1007/S00262-012-1369-3
P577
2012-12-08T00:00:00Z
P6179
1051917958